STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Diamyd Medical is currently experiencing an exceptionally intensive period with extremely high expectations on the company, both internally and externally. In mid-February, the last patient made the final visit in the 15-month main trial period in the company’s European Phase III trial. Participants in the study are being treated with the antigen-based candidate drug Diamyd® or placebo to assess whether it is possible to preserve beta cell function and thus improve management of blood sugar control long term among children and adolescents with recent-onset type 1 diabetes. Extensive efforts are currently underway to compile and process all the data. This is a comprehensive and time-consuming undertaking and, as previously announced, we expect to be able to report the top line results from the study in the late spring.
